This multicentric observational study evaluates a nutraceutical combination based on Tanacetum Parthenium (in Parthenolid), 5-hydroxytryptophan (5-HTP), derived from Griffonia simplicifolia and magnesium (AuraSTOP®) in episodic migraine.

Episodic migraine is defined by the presence of less than 15 days of headache per month, but it still represents a highly disabling condition, with a significant impact on the quality of life, work productivity and psychophysical well-being of patients1.

The main objective of the study was to evaluate the reduction in the monthly frequency of migraine attacks in subjects taking with AuraSTOP© for 3 months. Secondary endpoints included the change in pain intensity, the reduction in the number of days with headache, the consumption of symptomatic drugs and the tolerability of the treatment.

The biological rationale of the combination is based on the main pathophysiological mechanisms of migraine. Tanacetum parthenium has anti-inflammatory properties and modulates the release of mediators involved in neuroinflammation and trigeminal-vascular sensitization2. 5-HTP, a direct precursor of serotonin, contributes to the regulation of serotonergic systems, notoriously implicated in the genesis of the migraine attack3. Magnesium, often deficient in migraines, plays a fundamental role in stabilizing neuronal membranes and modulating cortical excitability4.

The results of the multicentre study show a significant reduction in the frequency of monthly attacks in the treated subjects, with a parallel improvement in the intensity of the pain and a decrease in the use of analgesic drugs. The beneficial effect was progressive during the observation period, the safety profile appeared favorable, with mild and transitory side effects and a high adherence to integration.

The authors conclude that the combination of Tanacetum parthenium (standardized in parthenolide), 5-HTP and magnesium represents a promising option to support episodic migraine, especially in subjects who prefer a nutraceutical approach or who present contraindications or poor tolerability to traditional drug therapies. However, since it is an uncontrolled observational study, the need for randomized and controlled studies on larger samples is emphasized to define the role of this formulation among the available preventive strategies for migraine.

  1. Silbertstein SD., et al. Study summary: health care resource utilization and disability among patients treated for migraine. Headache. 2018;58(10):1579-1592.
  2. Wider B., et al. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4(4):CD002286.
  3. Aggarwal M., et al. Serotonin and CGRP in migraine. Ann Neurosci. 2012;19(2):88-94.
  4. Sun-Edelstein C., et al. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009;9(3):369-79.

Related articles